Old Web
English
Sign In
Acemap
>
authorDetail
>
Han Ting Ding
Han Ting Ding
Immunology
Bilirubin
Pharmacokinetics
Biology
Cirrhosis
2
Papers
9
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Phase I study of enavatuzumab, a first-in-class humanized monoclonal antibody targeting the TWEAK receptor, in patients with advanced solid tumors
2018
Molecular Cancer Therapeutics
Elaine T. Lam
S. Gail Eckhardt
Wells A. Messersmith
Antonio Jimeno
Cindy L. O'Bryant
Ramesh K. Ramanathan
Glen J. Weiss
Manpreet Chadha
Abbie Oey
Han Ting Ding
Patricia A. Culp
Stephan F Keller
Vivian Zhao
L. Claire Tsao
Anil Singhal
Kyle D. Holen
Daniel D. Von Hoff
Show All
Source
Cite
Save
Citations (8)
Abstract C18: A phase I study of enavatuzumab (PDL192, ABT-361), a first-in-class human monoclonal antibody targeting TWEAK (tumor necrosis factor-like inducer of apoptosis) receptor, in patients (Pts) with advanced solid tumors.
2011
Molecular Cancer Therapeutics
Elaine T. Lam
S. Gail Eckhardt
Wells A. Messersmith
Antonio Jimeno
Cindy L. O'Bryant
Ramesh K. Ramanathan
Glen J. Weiss
Manpreet Chadha
Monica Fulk
Ranay Yarian
Abbie Oey
Han Ting Ding
Patricia A. Culp
Teresa Parli
Claire Tsao
Anil K. Singhal
Mihail Obrocea
Kyle D. Holen
Daniel D. Von Hoff
Show All
Source
Cite
Save
Citations (1)
1